Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M 

TLDR Telix H1 revenue rises 22% to $477M as adjusted EBITDA jumps 146% year over year. Precision Medicine revenue climbs 27% as Illuccix and Gozellix drive higher sales. Telix invests $124M in R&D while advancing prostate, kidney and brain programs. Manufacturing revenue reaches $146M as Telix expands its global production footprint. Telix ends June with [...]

The post Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M  appeared first on Blockonomi.